All In Biotech

Drug Trial Radar · NCT02597803

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1

A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye: ARISE-1

Last checked: Nov 19, 2026Latest source record: Oct 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 317 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

317

Actual

Start

Sep 2015

Primary completion

Jun 2016

Study completion Jul 2016

Sponsor

Lead sponsor
ReGenTree, LLCIndustry
Sponsor type
Industry
First posted
Nov 5, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.

Conditions

  • Dry Eye Syndrome

Interventions

  • RGN-259Drug

    A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days

  • PlaceboDrug

    It is composed of the same excipients as RGN-259 but does not contain Tβ4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total corneal fluorescein staining score at day29Time frame: 29 days after first dosing
  2. Total ocular discomfort score at day29Time frame: 29 days after first dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Andover, MA

    Andover, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.